Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Crystallization of organic compounds [[electronic resource] ] : an industrial perspective / / Hsien-Hsin Tung ... [et al.]
| Crystallization of organic compounds [[electronic resource] ] : an industrial perspective / / Hsien-Hsin Tung ... [et al.] |
| Autore | Tung Hsien-Hsin <1955-> |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2009 |
| Descrizione fisica | 1 online resource (304 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) | TungHsien-Hsin <1955-> |
| Soggetto topico |
Crystallization - Industrial applications
Pharmaceutical chemistry Pharmaceutical industry |
| ISBN |
1-282-36829-X
9786612368295 0-470-44779-6 0-470-44778-8 |
| Classificazione | VE 9500 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Crystallization of Organic Compounds; Contents; Preface; 1. Introduction to Crystallization Issues; 1.1 Crystal Properties and Polymorphism (Chapters 2 and 3); 1.2 Nucleation and Growth Kinetics (Chapter 4); 1.3 Critical Issues (Chapter 5); 1.4 Mixing and Crystallization (Chapter 6); 1.5 Crystallization Process Options (Chapters 7-10); 1.6 Special Applications (Chapter 11); 1.7 Regulatory Issues; 2. Properties; 2.1 Solubility; 2.2 Supersaturation, Metastable Zone, and Induction Time; 2.3 Oil, Amorphous, and Crystalline States; 2.4 Polymorphism; 2.5 Solvate
2.6 Solid Compound, Solid Solution, and Solid Mixture2.7 Inclusion and Occlusion; 2.8 Adsorption, Hygroscopicity, and Deliquescence; 2.9 Crystal Morphology; 2.10 Particle Size Distribution and Surface Area; 3. Polymorphism; 3.1 Phase Rule; 3.2 Phase Transition; 3.3 Examples; Example 3-1 Indomethacin; Example 3-2 Sulindac; Example 3-3 Losartan; Example 3-4 Finasteride; Example 3-5 Ibuprofen Lysinate; Example 3-6 HCl Salt of a Drug Candidate; Example 3-7 Second HCl Salt of a Drug Candidate; Example 3-8 Prednisolone t-Butylacetate; Example 3-9 Phthalylsulfathiazole; 3.4 Future Direction 4. Kinetics4.1 Supersaturation and Rate Processes; 4.2 Nucleation; 4.3 Crystal Growth; 4.4 Nucleate/Seed Aging and Ostwald Ripening; 4.5 Delivered Product: Size Distribution and Morphology; 5. Critical Issues in Crystallization Practice; 5.1 Introduction; 5.2 Nucleation; 5.3 Growth; 5.4 Oiling Out, Agglomeration/Aggregation; 5.5 Seeding; 5.6 Rate of Generation of Supersaturation; 5.7 Summary of Critical Issues; 6. Mixing and Crystallization; 6.1 Introduction; 6.2 Mixing Considerations; 6.3 Mixing Effects on Nucleation; 6.4 Mixing Effects on Crystal Growth; 6.5 Mixing Scale-up 6.6 Crystallization EquipmentExample 6-1; 7. Cooling Crystallization; 7.1 Batch Operation; 7.2 Continuous Operations; 7.3 Process Design-Examples; Example 7-1 Intermediate in a Multistep Synthesis; Example 7-2 Pure Crystallization of an API; Example 7-3 Crystallization Using the Heel from the Previous Batch as Seed; Example 7-4 Resolution of Ibuprofen Via Stereospecific Crystallization; Example 7-5 Crystallization of Pure Bulk with Polymorphism; Example 7-6 Continuous Separation of Stereoisomers; 8. Evaporative Crystallization; 8.1 Introduction; 8.2 Solubility Diagrams 8.3 Factors Affecting Nucleation and Growth8.4 Scale-up; 8.5 Equipment; Example 8-1 Crystallization of a Pharmaceutical Intermediate Salt; Example 8-2 Crystallization of the Sodium Salt of a Drug Candidate; 9. Antisolvent Crystallization; 9.1 Semibatch Operation; Example 9-1 Crystallization of an Intermediate; Example 9-2 Rejection of Isomeric Impurities of Final Bulk Active Product; Example 9-3 Crystallization of a Pharmaceutical Product with Poor Nucleation and Growth Characteristics; Example 9-4 Impact of Solvent and Supersaturation on Particle Size and Crystal Form 9.2 In-Line Mixing Crystallization |
| Record Nr. | UNINA-9910139989303321 |
Tung Hsien-Hsin <1955->
|
||
| Hoboken, N.J., : Wiley, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Crystallization of organic compounds : an industrial perspective / / Hsien-Hsin Tung ... [et al.]
| Crystallization of organic compounds : an industrial perspective / / Hsien-Hsin Tung ... [et al.] |
| Autore | Tung Hsien-Hsin <1955-> |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2009 |
| Descrizione fisica | 1 online resource (304 p.) |
| Disciplina | 615/.19 |
| Soggetto topico |
Crystallization - Industrial applications
Pharmaceutical chemistry Pharmaceutical industry |
| ISBN |
9786612368295
9781282368293 128236829X 9780470447796 0470447796 9780470447789 0470447788 |
| Classificazione | VE 9500 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Crystallization of Organic Compounds; Contents; Preface; 1. Introduction to Crystallization Issues; 1.1 Crystal Properties and Polymorphism (Chapters 2 and 3); 1.2 Nucleation and Growth Kinetics (Chapter 4); 1.3 Critical Issues (Chapter 5); 1.4 Mixing and Crystallization (Chapter 6); 1.5 Crystallization Process Options (Chapters 7-10); 1.6 Special Applications (Chapter 11); 1.7 Regulatory Issues; 2. Properties; 2.1 Solubility; 2.2 Supersaturation, Metastable Zone, and Induction Time; 2.3 Oil, Amorphous, and Crystalline States; 2.4 Polymorphism; 2.5 Solvate
2.6 Solid Compound, Solid Solution, and Solid Mixture2.7 Inclusion and Occlusion; 2.8 Adsorption, Hygroscopicity, and Deliquescence; 2.9 Crystal Morphology; 2.10 Particle Size Distribution and Surface Area; 3. Polymorphism; 3.1 Phase Rule; 3.2 Phase Transition; 3.3 Examples; Example 3-1 Indomethacin; Example 3-2 Sulindac; Example 3-3 Losartan; Example 3-4 Finasteride; Example 3-5 Ibuprofen Lysinate; Example 3-6 HCl Salt of a Drug Candidate; Example 3-7 Second HCl Salt of a Drug Candidate; Example 3-8 Prednisolone t-Butylacetate; Example 3-9 Phthalylsulfathiazole; 3.4 Future Direction 4. Kinetics4.1 Supersaturation and Rate Processes; 4.2 Nucleation; 4.3 Crystal Growth; 4.4 Nucleate/Seed Aging and Ostwald Ripening; 4.5 Delivered Product: Size Distribution and Morphology; 5. Critical Issues in Crystallization Practice; 5.1 Introduction; 5.2 Nucleation; 5.3 Growth; 5.4 Oiling Out, Agglomeration/Aggregation; 5.5 Seeding; 5.6 Rate of Generation of Supersaturation; 5.7 Summary of Critical Issues; 6. Mixing and Crystallization; 6.1 Introduction; 6.2 Mixing Considerations; 6.3 Mixing Effects on Nucleation; 6.4 Mixing Effects on Crystal Growth; 6.5 Mixing Scale-up 6.6 Crystallization EquipmentExample 6-1; 7. Cooling Crystallization; 7.1 Batch Operation; 7.2 Continuous Operations; 7.3 Process Design-Examples; Example 7-1 Intermediate in a Multistep Synthesis; Example 7-2 Pure Crystallization of an API; Example 7-3 Crystallization Using the Heel from the Previous Batch as Seed; Example 7-4 Resolution of Ibuprofen Via Stereospecific Crystallization; Example 7-5 Crystallization of Pure Bulk with Polymorphism; Example 7-6 Continuous Separation of Stereoisomers; 8. Evaporative Crystallization; 8.1 Introduction; 8.2 Solubility Diagrams 8.3 Factors Affecting Nucleation and Growth8.4 Scale-up; 8.5 Equipment; Example 8-1 Crystallization of a Pharmaceutical Intermediate Salt; Example 8-2 Crystallization of the Sodium Salt of a Drug Candidate; 9. Antisolvent Crystallization; 9.1 Semibatch Operation; Example 9-1 Crystallization of an Intermediate; Example 9-2 Rejection of Isomeric Impurities of Final Bulk Active Product; Example 9-3 Crystallization of a Pharmaceutical Product with Poor Nucleation and Growth Characteristics; Example 9-4 Impact of Solvent and Supersaturation on Particle Size and Crystal Form 9.2 In-Line Mixing Crystallization |
| Record Nr. | UNINA-9910816988403321 |
|
Tung Hsien-Hsin <1955->
|
||
| Hoboken, N.J., : Wiley, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||